Macitentan for treatment of CTEPH: why MERIT merits attention
Publication
, Journal Article
Torbicki, A
Published in: The Lancet Respiratory Medicine
October 2017
Duke Scholars
Published In
The Lancet Respiratory Medicine
DOI
ISSN
2213-2600
Publication Date
October 2017
Volume
5
Issue
10
Start / End Page
762 / 763
Publisher
Elsevier BV
Related Subject Headings
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1199 Other Medical and Health Sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Torbicki, A. (2017). Macitentan for treatment of CTEPH: why MERIT merits attention. The Lancet Respiratory Medicine, 5(10), 762–763. https://doi.org/10.1016/s2213-2600(17)30342-9
Torbicki, Adam. “Macitentan for treatment of CTEPH: why MERIT merits attention.” The Lancet Respiratory Medicine 5, no. 10 (October 2017): 762–63. https://doi.org/10.1016/s2213-2600(17)30342-9.
Torbicki A. Macitentan for treatment of CTEPH: why MERIT merits attention. The Lancet Respiratory Medicine. 2017 Oct;5(10):762–3.
Torbicki, Adam. “Macitentan for treatment of CTEPH: why MERIT merits attention.” The Lancet Respiratory Medicine, vol. 5, no. 10, Elsevier BV, Oct. 2017, pp. 762–63. Crossref, doi:10.1016/s2213-2600(17)30342-9.
Torbicki A. Macitentan for treatment of CTEPH: why MERIT merits attention. The Lancet Respiratory Medicine. Elsevier BV; 2017 Oct;5(10):762–763.
Published In
The Lancet Respiratory Medicine
DOI
ISSN
2213-2600
Publication Date
October 2017
Volume
5
Issue
10
Start / End Page
762 / 763
Publisher
Elsevier BV
Related Subject Headings
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1199 Other Medical and Health Sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences